By Rob Curran

 

Elanco Animal Health received a conditional U.S. Department of Agriculture license for the treatment of a common canine virus.

The veterinary-medicine maker said its Canine Parvovirus Monoclonal Antibody targets a highly contagious virus that has a mortality rate of 91% in dogs, if untreated.

Elanco, which was spun off from Eli Lilly & Co. in 2019, said it expects to begin shipping the product in the coming weeks, pending state approvals.

 

Write to Rob Curran at rob.curran@dowjones.com

 

(END) Dow Jones Newswires

May 02, 2023 09:06 ET (13:06 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Elanco Animal Health Charts.
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Elanco Animal Health Charts.